Alabama § 22-5D-3 Availability to Eligible Patient of Investigational Drug, Biological Product, or Device

Alabama Statutes

§ 22-5D-3 — Availability to Eligible Patient of Investigational Drug, Biological Product, or Device

Alabama § 22-5D-3

Title 22Health, Mental Health, and Environmental Control

Ch. 5DGabe Griffin Right to Try Act

This text of Alabama § 22-5D-3 (Availability to Eligible Patient of Investigational Drug, Biological Product, or Device) is published on Counsel Stack Legal Research, covering Alabama primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Ala. Code § 22-5D-3 (2026).

Text

(a)The manufacturer of an investigational drug, biological product, or device may make available and an eligible patient may request the manufacturer’s investigational drug, biological product, or device under this chapter. This chapter does not require that a manufacturer make available an investigational drug, biological product, or device to an eligible patient.

(b)A manufacturer may do all of the following:

(1)Provide an investigational drug, biological product, or device to an eligible patient without receiving compensation.

(2)Require an eligible patient to pay the costs of, or the costs associated with, the manufacture of the investigational drug, biological product, or device.

Free access — add to your briefcase to read the full text and ask questions with AI

(a) The manufacturer of an investigational drug, biological product, or device may make available and an eligible patient may request the manufacturer’s investigational drug, biological product, or device under this chapter. This chapter does not require that a manufacturer make available an investigational drug, biological product, or device to an eligible patient.
(b) A manufacturer may do all of the following:
(1) Provide an investigational drug, biological product, or device to an eligible patient without receiving compensation.
(2) Require an eligible patient to pay the costs of, or the costs associated with, the manufacture of the investigational drug, biological product, or device.